Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver

Authors

  • Claudia Cicione,

    1. Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy
    Search for more papers by this author
  • Chiara Degirolamo,

    1. Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy
    Search for more papers by this author
  • Antonio Moschetta

    Corresponding author
    1. Laboratory of Lipid Metabolism and Cancer, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy
    2. Clinica Medica “A. Murri,” Department of Internal and Public Medicine, University of Bari, Policlinico, Bari, Italy
    3. National Cancer Institute Giovanni Paolo II, Bari, Italy
    • University of Bari, Consorzio Mario Negri Sud, Via Nazionale 8/A, 66030 Santa Maria Imbaro (Chieti), Italy

    Search for more papers by this author
    • fax: +39-0872-570299


  • Potential conflict of interest: Nothing to report.

  • The work was funded by the Italian Association for Cancer Research (IG 10416; Milan, Italy, the Italian Ministry of Health and Education (Finanziamenti per la Ricerca di Base IDEAS RBID08C9N7), the Italian Ministry of Health (Young Researchers Grant 2008, GR-2008-1143546), the European Community's Seventh Framework Program FP7/2007–2013 under Grant Agreement No. 202272 (LipidomicNet), and the Cariplo Fundation Milan, University of Bari, Bari, Italy (ORBA 08WEZJ, 07X7Q1, 06BXVC, and IDEA GRBA0802SJ).

Abstract

Fibroblast growth factors (FGFs) 15/19 and 21 belong to the FGF endocrine subfamily. They present the intriguing characteristic to be transcribed and secreted in certain tissues and to act as hormones. The insulin-mimetic properties of FGF21 and the regulatory role of FGF15/19 in bile acid and glucose homeostasis endorse these hormones as druggable targets in metabolic disorders. Here, we present details on discoveries, identification, transcriptional regulation, and mechanism of actions of FGF15/19 and FGF21 with a critical perspective view on their putative role as metabolic integrators in the liver. (HEPATOLOGY 2012;56:2404–2411)

Ancillary